{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:33:21Z","timestamp":1777901601259,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s12325-011-0005-5","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T05:16:53Z","timestamp":1301548613000},"page":"251-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Jean-Luc","family":"Vachi\u00e9ry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N. Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493\u20132537.","journal-title":"Eur Heart J"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G. Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43\u2013S54.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR3","first-page":"603","volume":"110","author":"P. Jansa","year":"2009","unstructured":"Jansa P, Ambroz D, Maresova J, Polacek P, Aschermann M, Linhart A. Pulmonary arterial hypertension-contemporary management strategy. Bratisl Lek Listy. 2009;110:603\u2013608.","journal-title":"Bratisl Lek Listy"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/13543781003727099","volume":"19","author":"L. Dewachter","year":"2010","unstructured":"Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs. 2010;19:469\u2013488.","journal-title":"Expert Opin Investig Drugs"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1155\/2010\/702836","volume":"2010","author":"S. Umar","year":"2010","unstructured":"Umar S, Steendijk P, Ypey DL, et al. Novel approaches to treat experimental pulmonary arterial hypertension: a review. J Biomed Biotechnol. 2010;2010:702\u2013836.","journal-title":"J Biomed Biotechnol"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"B. Christman","year":"1992","unstructured":"Christman B, McPherson C, Newman J, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70\u201375.","journal-title":"N Engl J Med"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","volume":"159","author":"R. Tuder","year":"1999","unstructured":"Tuder R, Cool C, Geraci M, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925\u20131932.","journal-title":"Am J Respir Crit Care Med"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1183\/09031936.00097107","volume":"31","author":"M. Gomberg-Maitland","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31:891\u2013901.","journal-title":"Eur Respir J"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","volume":"104","author":"K.K. Mubarak","year":"2010","unstructured":"Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104:9\u201321.","journal-title":"Respir Med"},{"key":"5_CR10","first-page":"485","volume":"112","author":"L.J. Rubin","year":"1990","unstructured":"Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485\u2013491.","journal-title":"Results of a randomized trial. Ann Intern Med"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"R. Barst","year":"1996","unstructured":"Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"5_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"D.B. Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425\u2013434.","journal-title":"Ann Intern Med"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.healun.2008.12.003","volume":"28","author":"W. Jacobs","year":"2009","unstructured":"Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. J Heart Lung Transplant. 2009;28:280\u2013284.","journal-title":"J Heart Lung Transplant"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","volume":"167","author":"K.P. Kuhn","year":"2003","unstructured":"Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167:580\u2013586.","journal-title":"Am J Respir Crit Care Med"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O. Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780\u2013788","journal-title":"J Am Coll Cardiol"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"V.V. McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477\u20131482.","journal-title":"Circulation"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1378\/chest.08-1323","volume":"135","author":"K. Chin","year":"2009","unstructured":"Chin K, Channick R, de Lemos J, et al. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009;135:130\u2013136.","journal-title":"Chest"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","volume":"34","author":"S. Rich","year":"1999","unstructured":"Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1184\u20131187.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","volume":"149","author":"G. Simonneau","year":"2008","unstructured":"Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521\u2013530.","journal-title":"Ann Intern Med"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","volume":"174","author":"V.V. McLaughlin","year":"2006","unstructured":"McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257\u20131263.","journal-title":"Am J Respir Crit Care Med"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","volume":"55","author":"V.V. McLaughlin","year":"2010","unstructured":"McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915\u20131922.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1183\/09031936.04.00028404","volume":"24","author":"M. Humbert","year":"2004","unstructured":"Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353\u2013359.","journal-title":"Eur Respir J"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1586\/14779072.2.2.183","volume":"2","author":"J.L. Vachiery","year":"2004","unstructured":"Vachiery JL, Naeije R. Treprostinil for pulmonary hypertension. Expert Rev Cardiovasc Ther. 2004;2:183\u2013191.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"5_CR24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G. Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800\u2013804.","journal-title":"Am J Respir Crit Care Med"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1378\/chest.07-2111","volume":"134","author":"R.L. Benza","year":"2008","unstructured":"Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest. 2008;134:139\u2013145.","journal-title":"Chest"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","volume":"28","author":"R.J. Barst","year":"2006","unstructured":"Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195\u20131203.","journal-title":"Eur Respir J"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","volume":"129","author":"I. Lang","year":"2006","unstructured":"Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129:1636\u20131643.","journal-title":"Chest"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1517\/14656566.9.8.1415","volume":"9","author":"N. Skoro-Sajer","year":"2008","unstructured":"Skoro-Sajer N, Lang I. Treprostinil for the treatment of pulmonary hypertension. Expert Opin Pharmacother. 2008;9:1415\u20131420.","journal-title":"Expert Opin Pharmacother"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2165\/00003088-200847090-00004","volume":"47","author":"N. Skoro-Sajer","year":"2008","unstructured":"Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet. 2008;47:611\u2013618.","journal-title":"Clin Pharmacokinet"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1378\/chest.129.3.683","volume":"129","author":"V.F. Tapson","year":"2006","unstructured":"Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683\u2013688.","journal-title":"Chest"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","volume":"29","author":"J. Hiremath","year":"2010","unstructured":"Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29:137\u2013149.","journal-title":"J Heart Lung Transplant"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","volume":"48","author":"R. Voswinckel","year":"2006","unstructured":"Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48:1672\u20131681.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pupt.2008.11.009","volume":"22","author":"R. Voswinckel","year":"2009","unstructured":"Voswinckel R, Reichenberger F, Gall H, et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009;22:50\u201356.","journal-title":"Pulm Pharmacol Ther"},{"key":"5_CR34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","volume":"124","author":"H. Olschewski","year":"1996","unstructured":"Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820\u2013824.","journal-title":"Ann Intern Med"},{"key":"5_CR35","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/01.CIR.101.20.2388","volume":"101","author":"R. Wensel","year":"2000","unstructured":"Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation. 2000;101:2388\u20132392.","journal-title":"Circulation"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H. Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322\u2013329.","journal-title":"N Engl J Med"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","volume":"26","author":"C.F. Opitz","year":"2005","unstructured":"Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895\u20131902.","journal-title":"Eur Heart J"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","volume":"104","author":"H. Olschewski","year":"2010","unstructured":"Olschewski H, Hoeper MM, Behr J, et al. Longterm therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104:731\u2013740.","journal-title":"Respir Med"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1253\/circj.71.1829","volume":"71","author":"D. Ikeda","year":"2007","unstructured":"Ikeda D, Tsujino I, Sakaue S, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J. 2007;71:1829\u20131831.","journal-title":"Circ J"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","volume":"39","author":"N. Galie","year":"2002","unstructured":"Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496\u20131502.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","volume":"41","author":"R.J. Barst","year":"2003","unstructured":"Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119\u20132125.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","volume":"34","author":"N. Nagaya","year":"1999","unstructured":"Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188\u20131192.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/heart.87.4.340","volume":"87","author":"N. Nagaya","year":"2002","unstructured":"Nagaya N, Shimizu Y, Satoh T, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart. 2002;87:340\u2013345.","journal-title":"Heart"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1378\/chest.123.5.1583","volume":"123","author":"F. Ono","year":"2003","unstructured":"Ono F, Nagaya N, Okumura H, et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest. 2003;123:1583\u20131588.","journal-title":"Chest"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00003495-200262010-00005","volume":"62","author":"E.B. Melian","year":"2002","unstructured":"Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62:107\u2013133.","journal-title":"Drugs"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"R.J. Barst","year":"2009","unstructured":"Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54;S78\u2013S84.","journal-title":"J Am Coll Cardiol"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","volume":"44","author":"K. Laliberte","year":"2004","unstructured":"Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44:209\u2013214.","journal-title":"J Cardiovasc Pharmacol"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/00005344-199311000-00007","volume":"22","author":"J.L. Demolis","year":"1993","unstructured":"Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol. 1993;22:711\u2013716.","journal-title":"J Cardiovasc Pharmacol"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1183\/09059180.00008010","volume":"19","author":"J.L. Vachiery","year":"2010","unstructured":"Vachiery JL, Simonneau G. Management of severe pulmonary arterial hypertension. Eur Respir Rev. 2010;19:279\u2013287.","journal-title":"Eur Respir Rev"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"V.V. McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB, et al. ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250\u20132294.","journal-title":"Circulation"},{"key":"5_CR51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"R. Benza","year":"2010","unstructured":"Benza R, Miller D, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164\u2013172.","journal-title":"Circulation"},{"key":"5_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1183\/09031936.00057010","volume":"36","author":"M. Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549\u2013555.","journal-title":"Eur Respir J"},{"key":"5_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jamp.2007.0657","volume":"21","author":"T. Gessler","year":"2008","unstructured":"Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21:1\u201312.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1592\/phco.30.7.728","volume":"30","author":"M.S. Buckley","year":"2010","unstructured":"Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010;30:728\u2013740.","journal-title":"Pharmacotherapy"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1742-1241.2008.01960.x","volume":"161","author":"J. Rich","year":"2009","unstructured":"Rich J, Hoeper MM. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer? Int J Clin Pract Suppl. 2009;161:17\u201318.","journal-title":"Int J Clin Pract Suppl"},{"key":"5_CR56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/VHRM.S2477","volume":"4","author":"N. Skoro-Sajer","year":"2008","unstructured":"Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Vasc Health Risk Manag. 2008;4:507\u2013513.","journal-title":"Vasc Health Risk Manag"},{"key":"5_CR57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2310\/JIM.0b013e318165e921","volume":"56","author":"C.M. Hart","year":"2008","unstructured":"Hart CM. The Role of PPARgamma in pulmonary vascular disease. J Investig Med. 2008;56:518\u2013521.","journal-title":"J Investig Med"},{"key":"5_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/978-1-60761-500-2_29","volume":"661","author":"M. Rabinovitch","year":"2010","unstructured":"Rabinovitch M. PPARgamma and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:447\u2013458.","journal-title":"Adv Exp Med Biol"},{"key":"5_CR59","doi-asserted-by":"publisher","first-page":"L885","DOI":"10.1152\/ajplung.00258.2006","volume":"292","author":"J.T. Crossno Jr.","year":"2007","unstructured":"Crossno JT, Jr., Garat CV, Reusch JE, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007;292:L885\u2013L897.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5_CR60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1165\/rcmb.2008-0132OC","volume":"42","author":"R.E. Nisbet","year":"2010","unstructured":"Nisbet RE, Bland JM, Kleinhenz DJ, et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol. 2010;42:482\u2013490.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5_CR61","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbrc.2007.06.135","volume":"360","author":"E. Falcetti","year":"2007","unstructured":"Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochem Biophys Res Commun. 2007;360:821\u2013827.","journal-title":"Biochem Biophys Res Commun"},{"key":"5_CR62","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMp1008233","volume":"363","author":"C.J. Rosen","year":"2010","unstructured":"Rosen CJ. Revisiting the rosiglitazone story-lessons learned. N Engl J Med. 2010;363:803\u2013806.","journal-title":"N Engl J Med"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.healun.2007.01.035","volume":"26","author":"R.L. Benza","year":"2007","unstructured":"Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007;26:437\u2013446.","journal-title":"J Heart Lung Transplant"},{"key":"5_CR64","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1097\/PCC.0b013e3181c76db3","volume":"11","author":"K.R. Stenmark","year":"2010","unstructured":"Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med. 2010;11:S85\u2013S90.","journal-title":"Pediatr Crit Care Med"},{"key":"5_CR65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.drudis.2008.12.003","volume":"14","author":"K.M. Olsson","year":"2009","unstructured":"Olsson KM, Hoeper MM. Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discov Today. 2009;14:284\u2013290..","journal-title":"Drug Discov Today"},{"key":"5_CR66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","volume":"122","author":"M. Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigenassociated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156\u2013163.","journal-title":"Circulation"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0005-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-011-0005-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0005-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0005-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:38:17Z","timestamp":1659098297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-011-0005-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s12325-011-0005-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,29]]},"assertion":[{"value":"26 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2011","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}